Phase II Trial in Inoperable œsophageal Cancer Evaluating the Feasibility of the Combination of Definitive Chemoradiation With the Immune Checkpoint Blockers Nivolumab plus minus Ipilimumab.

Trial Profile

Phase II Trial in Inoperable œsophageal Cancer Evaluating the Feasibility of the Combination of Definitive Chemoradiation With the Immune Checkpoint Blockers Nivolumab plus minus Ipilimumab.

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Jul 2018

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Adenocarcinoma; Oesophageal cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms CRUCIAL
  • Most Recent Events

    • 21 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top